NIH funds PTC to develop dengue treatment
The grant spread for a year will support research identified by PTC’s proprietary GEMS technology that demonstrates activity against the dengue virus. PTC grant collaborator Eva Harris said,
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Amicus is developing the investigational pharmacological chaperone Migalastat HCl under collaboration with GlaxoSmithKline. Study 012, designed to compare oral migalastat HCl to ERTs (Fabrazyme and Replagal), enrolled Fabry